Tetrahedron Letters Vol. 21, pp 1485 - 1488 © Pergamon Press Ltd. 1980. Printed in Great Britain 0040-4039/80/0415-1485\$02.00/0

THE SYNTHESIS OF A LEUKOTRIENE WITH SRS-LIKE ACTIVITY

Joshua Rokach*, Yves Girard, Yvan Guindon, Joseph G. Atkinson, Marie Larue, Robert N. Young, Paul Masson, and George Holme

Merck Frosst Research Laboratories, P.O. Box 1005, Pointe-Claire/Dorval, Quebec, Canada H9R 4P8

Summary: The synthesis and biological characteristics of an SRS-like leukotriene are described.

Since its discovery in 1938¹ SRS-A (slow reacting substance of anaphylaxis) has been implicated as one of the mediators released during anaphylactic reactions, and it may be the major mediator in allergic asthma. Although the biological properties of this substance including its release from various tissues by ionophores have been investigated extensively, its structure has remained elusive.

The recent report by Samuelsson² that the basic structure of SRS might be <u>1</u> stimulated our interest in a total synthesis of SRS. The suggestion by others³ that the amino acid portion of SRS might be glutathione rather than cysteine and the known effect of various thiols⁴ on yield enhancement for a family of isolates with SRS-like activity from rat peritoneal cells influenced the synthetic strategy which we developed and describe here.



Thus, our synthetic plan had to take into consideration three uncertainties: 1) the geometry of the 7,8- and 9,10-double bonds; 2) the stereochemistry of the 5,6-substituents; and 3) the exact nature of the sulfur-containing side chain.

In the present approach our initial target was the synthesis of alcohols 2, 3, and 4 from which we envisioned a number of alternatives to add the remaining 5-carbon piece.

The readily prepared diene ester aldehyde⁵ $\underline{5}$ and the commercially available alcohol $\underline{7}$ appeared to be excellent synthons for the assembly of these alcohols. Synthon $\underline{5}$ was selected because of its two readily distinguishable carbonyl functionalitites and the presence of two double bonds with the stereochemistry required in $\underline{1}$. In addition, the known transformation of $\underline{5}$ to $\underline{6}$ would be available should that alternative prove necessary (Scheme I).

The functionalization of $\underline{7}$ to yield $\underline{8-15}$ was straightforward⁶, as was the Wittig reaction of 12 (Z=C1) with $\underline{5}$ to yield ester <u>16</u>. However, on standing at room temperature for 1-2 days, <u>16</u>

was transformed to <u>17</u>. The same isomerization was observed with the product of the Wittig reaction between the acetylene <u>9</u> (Z=Br) and <u>5</u>. Disconcertingly, <u>3</u>, obtained (80-90%) by AlH₃ reduction of pure <u>16</u> also showed the same behaviour and, after 18 hours at room temperature it had isomerized to <u>18</u> to the extent of approximately 50%. These isomerizations presumably proceed by a particularly facile (1, 7)-hydrogen migration^{7a} as shown in <u>19</u>^{7b}.





At this point we felt that the observed propensity of the <u>trans</u>, <u>cis</u>, <u>cis</u>-triene unit to spontaneous isomerization cast serious doubts on the possibility that the 9,10-double bond in SRS was <u>cis</u>, since there is no obvious reason why a similar [1, 7]-hydrogen migration would not occur in that case as well. We therefore redirected our efforts to prepare the <u>trans</u>, <u>trans</u>, <u>cis</u>, <u>cis</u>-tetraene alcohol <u>21</u> by the same series of reactions using dienal ester <u>6</u> as shown in Scheme II⁸. The resulting ester <u>20</u> and derived alcohol <u>21</u> proved to be stable with respect to the [1, 7]-hydrogen migration, although they were prone to polymerization if kept neat.

Alcohol <u>21</u> was converted to the mesylate, dimethyl sulfonium salt and thence to the sulfonium ylid which condensed with methyl 5-oxopentanoate to provide a mixture of the epoxides <u>22</u> and <u>23</u>⁹ in low yield (10-20%). The <u>cis</u> and <u>trans</u> epoxides were readily separable by HPLC^{10} .

For the introduction of thio-substituents into position 6 of these epoxides, a novel, mild and general method for the stereospecific opening of epoxides using alkylthiotrimethylsilanes was devised¹¹. Model experiments indicated that the reaction was stereo- and regioselective as proved to be the case when applied to <u>22</u> and <u>23</u>, leading to the desired C-6 thio adducts.

Thus $\underline{22}$ and $\underline{23}$ reacted separately at 0°C in dichloroethane with the S-trimethylsilyl derivatives of cysteine methyl ester N-trifluoroacetamide^{12, 13}, glutathione dimethyl ester N-trifluoroacetamide, and other substituted thiotrimethylsilyl derivatives¹¹. After aqueous or methanolic work-up, two diastereoisomers were obtained from both the cysteine and glutathione additions to each epoxide. These were separated by HPLC. After basic hydrolysis (24 hours, K_2CO_3 , CH_3OH), the resultant products (essentially pure by reverse phase HPLC) were tested for biological activity. Only one of the compounds ($\underline{26}$)¹⁴, derived from the trans epoxide $\underline{22}$, and glutathione via the protected adduct $\underline{24}^{15}$, showed the potent activity characteristic of natural SRS¹⁶.

Scheme II



Compound <u>26</u> caused dose dependent contractions of the guines pig ileum and trachea with PD₂ values¹⁷ of approximately 8. The effects of <u>26</u> on the ileum and trachea were specifically antagonized by FPL 55712¹⁸ with pA₂ values¹⁷ of about 7. After incubation with lipoxidase (1 hour, 37°C), the biological activity of <u>26</u> was destroyed¹⁹, and the ultraviolet spectrum underwent a concurrent change, complete in 10 minutes at 25°C (λ_{max}^{MeOH} 280 \rightarrow 310 nm), identical with that published for natural SRS^{2b}.

<u>Acknowledgements</u>: We acknowledge W. Coombs and R. Frenette for the preparation of several intermediates and G. Brunet for the lipoxidase experiments. We thank Dr. B. Arison, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, for 300 MHz spectra. Professor S. Danishefsky generously provided a sample of methyl 5-oxopentanoate. We also thank Dr. P.S. Anderson, Merck Sharp & Dohme Laboratories, West Point, Pennsylvania, for encouragement and valuable discussions during the course of this work.

References and Notes

- 1. W. Feldberg and C.H. Kellaway, J. Physiol. (Lond.), 94, 187 (1938).
- a) First disclosed at the Fourth International Prostaglandin Conference, Washington, D.C., May 27-31, 1979.
 - b) R.C. Murphy, S. Hammarstrom and B. Samuelsson, Proc. Natl. Acad. Sci. U.S.A., <u>76</u>, 4275 (1979).
- C. Parker, International Congress on Prostaglandin Synthetase Inhibitors in Clinical Medicine, Sept. 27-28, 1979.
- 4. M.K. Bach and J.R. Brashler, Life Sciences, 23, 2119 (1978).
- 5. G.O. Schenck and R. Steinmetz, Ann., 668, 19 (1963).

- a) Bromides 8, <u>11</u>, and <u>14</u> were best prepared by the method of P.J. Kocienski,
 G. Cernigliaro and G. Feldstein, J. Org. Chem., <u>42</u>, 353 (1977).
 - b) Alcohols <u>10</u> and <u>13</u> were made from <u>7</u> using the P-2 nickel catalyst of C.A. Brown and V.K. Ahuja, Chem. Commun., 553 (1973).
 - c) The phosphonium salts 9, 12, and 15 (Z=Br) were prepared by quaternization of the corresponding bromides, the iodide salts by reaction of the alkyl bromides with NaI followed by quaternization, and the chloride salts by ion exchange with the bromides.
- 7. a) C.W. Spangler, Chem. Rev., 76, 187 (1976).
 - b) The isomerization can be monitored by a shift in the UV spectrum: λ_{max}^{MeOH} (260 sh, 269, 279 \rightarrow 287, 303, 317 nm) and by the appearance of the -CH₂CH₂OH unit in the PMR spectrum.
- 8. It is interesting to note that while <u>15</u> (Z=C1) gave approximately 90% <u>cis</u> geometry in the Wittig reaction, the bromide and iodide salts under the same conditions gave significantly more <u>trans</u> olefin. The undesired <u>trans</u> isomer can be removed by preparative HPLC.
- The structure of the <u>cis/trans</u> epoxides was disclosed originally by E.J. Corey (ref. 2a) and the preparation of this mixture has subsequently been published. E.J. Corey, Y. Arai and C. Mioskowski, J. Am. Chem. Soc., <u>101</u>, 6748 (1979).
- 10. μ -Porasil column by Waters Associates, hexane, ethyl acetate, triethylamine/100:1:1.
 - 22: $\lambda_{\text{max}}^{\text{MeOH}}$ 269, 278, 290 nm (ε 30,900, 37,800, 30,300), PMR (300 MHz, C₆D₆) confirmed structure; signals for epoxide protons at δ 2.98 (H6) and δ 2.65 (H5), J_{5,6} = 2.1 Hz. 23: $\lambda_{\text{max}}^{\text{MeOH}}$ 269, 278, 290 nm (ε 33,000, 47,500, 29,900), PMR (300 MHz, C₆D₆) confirmed structural assignment; epoxide protons at δ 3.21 (H6) and δ 2.77 (H5), J_{5,6} = 4.2 Hz.
- 11. Manuscript in preparation.
- 12. We found in model experiments that Cbz was unsatisfactory as a blocking group for nitrogen, and that the formyl group, while acceptable, required a stronger base (1N NaOH) and longer reaction time for complete hydrolysis.
- 13. The R-S-Si(CH₃)₃ derivatives were prepared in <u>situ</u> by treatment of the thiols with n-BuLi (1 eq., ClCH₂CH₂Cl, R.T.) then (CH₃)₃SiCl (1 eq., 0° C).
- 14. $\lambda_{\max}^{\text{MeOH}}$ 270, 280, 290 nm. Our synthesis proves that C-5 and C-6 are in the erythro configuration, having been formed from the <u>trans</u> epoxide, but does not indicate the absolute stereochemistry since the epoxide is racemic.
- 15. Homogeneous by HPLC, μ -Bondapack CN, heptane, methylene chloride, methanol/85:15:1.5. λ_{\max}^{MeOH} 265 sh, 278, 288 nm.
- 16. After the completion of this manuscript, a publication appeared describing the positive identification of leukotriene C₁ (SRS) as having the glutathione side chain: S. Hammerstrom, R.C. Murphy, B. Samuelsson, D.A. Clark, C. Mioskowski and E.J. Corey, Biochem. and Biophys. Res. Commun., 91, 1266 (1979).

We repeated the ring opening of our <u>trans</u> epoxide $\underline{22}$ with glutathione and triethylamine, as described in the cited paper. One of the two diastereoisomers obtained is identical by UV, HPLC retention time and biological activity with 26 prepared with our reagent.

- 17. F.G. Van den Brink and E.J. Lien, Eur. J. Pharmac., 44, 251 (1977).
- 18. N. Chand, Agents and Actions, 9, 133 (1979).
- 19. P. Sirois, Prostaglandins, 17, 395 (1979).

(Received in USA 7 February 1980)